Investing Your Stimulus Check: Should You Buy Pfizer Shares?

With vaccines seemingly being the solution to the ending of the COVID-19 pandemic, many people are wondering if Pfizer stock is a good buy?
Sept. 11, 2021
Unlock Free Stock Insights + 50% Off Discount Code!
Join thousands of savvy investors and get:
  • Weekly Stock Picks: Handpicked from 60,000 global options.
  • Ten Must-Have Stocks: Essential picks to hold until 2034.
  • Exclusive Stock Library: In-depth analysis of 60 top stocks.
  • Proven Success: 10-year track record of outperforming the market.
Sign up to our mailing list now and enjoy a 50% discount on premium services!
By submitting your email address, you consent to us keeping you informed about updates to our website and about other products and services that we think might interest you. You can unsubscribe at any time. Please read our Privacy Policy and Terms of Use.

The COVID-19 pandemic has caused a huge amount of disruption across the world for the past 18 months or so, with many businesses crippled due to extensive closures. However, green shoots started appearing when talk of effective vaccines against the virus were on their way. One of the companies to come to the fore with a vaccine was Pfizer (NYSE: PFE). This article will look at if Pfizer stock is a good investment. 

The bull case for Pfizer 

The main bull case for Pfizer is its COVID-19 vaccine. As one of the leading pharma companies, it has been at the forefront of helping the world get back to normal. Pharma companies have already distributed billions of vaccine doses across the world, with many more to come. With talk that annual booster shots will likely be needed, Pfizer looks well-positioned for sustained good performance in this business segment for the coming years.

In 2021, revenue from the Pfizer vaccine is set to be about $33.5 billion. To put this into perspective, Pfizer's total revenue last year was $41.9 billion. Therefore, Pfizer is benefitting massively from the rollout of vaccines.

As well as the COVID-19 vaccines, Pfizer is still focusing on releasing other types of medicines each and every year. The pandemic has not halted these efforts and it got three new approvals in Q2 2021. It has a good track record of bringing new medicines to the market to good effect.The company has also been trimming down areas of the business that are underperforming. This includes the spinning off of its Upjohn subsidiary which manufacturers generic drugs. Therefore, margins are expected to improve going forward. As well as an appreciating share price, investors are also expecting bigger dividend payouts going forward as a result of the company's success in recent quarters. Therefore, it looks to be a good long-term prospect.

The bear case for Pfizer 

Some people will point towards growing competition in the COVID-19 vaccination space as being something that will reign in Pfizer's revenues in the coming years. Certain investors see the pandemic as being a black swan event that will only give Pfizer a temporary boost in revenue and profit. Therefore, they do not seem to think that a higher share price will be justified based on a long-term horizon. 

So, should I buy Pfizer stock? 

Pfizer stock looks to be a good long-term buy. It is well-positioned to take advantage of the COVID-19 vaccination rollout and booster programs in the coming years. It has strong fundamentals, a good portfolio of other medicines, and a strong dividend. Therefore, it is a good choice for people looking to get some exposure in the pharma sector. 

If pharma companies aren't your thing, never fear; because with a MyWallSt subscription you will have access to our shortlist of market-beating stocks. Start your free access now.

Quickfire round: 

Who is the Pfizer CEO?

Albert Bourla has been the CEO of Pfizer since January 2019.

Does Pfizer pay a dividend?

Yes, Pfizer paid out $8.4 billion in dividends last year.

Is Pfizer profitable?

Yes, Pfizer generated a net profit of $9.6 billion in 2020.


Unlock Free Stock Insights +50% Off Discount Code!
Join thousands of savvy investors and get:
  • Weekly Stock Picks: Handpicked from 60,000 global options.
  • Ten Must-Have Stocks: Essential picks to hold until 2034.
  • Exclusive Stock Library: In-depth analysis of 60 top stocks.
  • Proven Success: 10-year track record of outperforming the market.
Sign up to our mailing list now and enjoy a 50% discount on premium services!
By submitting your email address, you consent to us keeping you informed about updates to our website and about other products and services that we think might interest you. You can unsubscribe at any time. Please read our Privacy Policy and Terms of Use.

The Home of Successful Investing.

© 2024 MyWallSt Ltd. All rights reserved.


Services

Content

Social

Company

Support

Resources


This website is operated by MyWallSt Ltd (“MyWallSt”). MyWallSt is a publisher and a technology platform, not a registered broker-dealer or registered investment adviser, and does not provide investment advice. All information provided by MyWallSt Limited is of a general nature for information and education purposes, and you should not construe any such information as investment advice. MyWallSt Limited does not take your specific needs, investment objectives or financial situation into consideration, and any investments mentioned may not be suitable for you. You should always carry out your own independent verification of facts and data before making any investment decisions, as we cannot guarantee the accuracy or completeness of any information we publish and any opinions that we publish may be wrong and may change at any time without notice. If you are unsure of any investment decision you should seek a professional financial advisor. MyWallSt Limited is not a registered investment adviser and we do not provide regulated investment advice or recommendations. MyWallSt Limited is not regulated by the Central Bank of Ireland. MyWallSt Limited may provide hyperlinks to web sites operated by third parties. Your use of third party web sites and content, including without limitation, your use of any information, data, advertising, products, or other materials on or available through such web sites, is at your own risk and is subject to the third parties' terms of use.